IMDS Investor Relations

IMDS Investor Relations Message

CT Laser Mammography Study Cites Importance of Assessing Breast Angiogenesis in Cancer Cases
Study Published in the Egyptian Journal of Radiology and Nuclear Medicine
Fort Lauderdale, Florida, April 10, 2007�Imaging Diagnostic Systems, Inc., (OTCBB:IMDS), a pioneer in laser optical breast imaging systems, announced the publication of a significant medical study, �Role of CTLM in Early Detection of Vascular Breast Lesions.� The paper, by Mohammed Emad E. Eid, M.D., Ph.D., et al., was published in The Egyptian Journal of Radiology and Nuclear Medicine, Vol. 37, No. 1, (March): 633-643, 2006.
The study highlighted the importance of imaging the presence and extent of angiogenesis in breasts as a means to improve breast cancer detection and management methods. Angiogenesis is the formation of new blood vessels. In the breast, such new vessels are associated with cancer growth.
According to Tim Hansen, IDSI Chief Executive Officer, �Dr. Emad�s work, conducted on 450 breasts, cites the problems with conventional breast imaging techniques and emphasizes the important role our new CT Laser Mammography system (CTLM�) can play in improving detection and management. The only other technique to image neovascularization is MRI; CTLM is less invasive, less expensive, and may have sensitivity advantages.�
The CTLM procedures were performed by Dr. Emad in the Department of Radiology, SAQR Hospital, RAK, United Arab Emirates.
In the United States, Imaging Diagnostic Systems is seeking FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography (CTLM�) system to be used as an adjunct to mammography. The FDA has determined that the Company�s clinical investigation is a non-significant risk (NSR) investigational device study because it does not meet the definition of a significant risk (SR) device under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The Imaging Diagnostic Systems CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.
As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company�s filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.
Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com

############################
You are subscribed to the following list: IMDS Investor Relations
Using the following email:
example@example.com
You may automatically unsubscribe from this list at any time by
visiting the following URL: <http://www.imds.com/cgi-bin/dada/mail.cgi/u/investor-relations/>;
If the above URL is inoperable, make sure that you have copied the
entire address. You may also change your subscription by
visiting this list's main screen:
<http://www.imds.com/cgi-bin/dada/mail.cgi/list/investor-relations>;
Imaging Diagnostic Systems, Inc. - 6531 NW 18th Court - Plantation, Florida 33313
Tel: 954.581.9800 / Fax: 954.581.0555
<mailto:obrien@imds.com>

IMDS Investor Relations Message

Imaging Diagnostic Systems Updates Patent Scorecard
Fort Lauderdale, Florida, January 30, 2007 - Imaging Diagnostic Systems, Inc., (OTCBB:IMDS), a pioneer in laser optical breast imaging systems, announced the issuance of U.S. Patent 7,155,274, entitled �Optical Computed Tomography Scanner for Small Laboratory Animals,� its 17th US patent in the optical CT field.

�This patent covers the key claims of our Laser Imager for Laboratory Animals (LILA), and is the cornerstone of the intellectual property being exclusively licensed to Bioscan, Inc., a Washington, DC, company that intends to commercialize the technology. Specifically, this patent protects the concepts of a helical optical CT scanner optimized for simultaneously imaging attenuation and fluorescence in small laboratory animals,� stated Robert Wake, IDSI�s VP of Engineering.
IDSI also noted that, since a previous release on US patents issued in 2004, 9 international patents have issued to IDSI, more than doubling IDSI�s international patent portfolio to 15 and its total portfolio to 32 patents. �Our main business is human breast optical imaging with CTLM systems, where we command a leadership position, as evidenced by our global portfolio,� commented Wake.
Recent international patents include:
Australian patent 775069, issued July 2004; European patent EP01181511, issued June 2005; Hong Kong patent HK1043480, issued January 2006; and German patent DE69925869 issued May 2006; all entitled �Laser Imaging Apparatus Using Biomedical Markers That Bind to Cancer Cells�. These 4 patents, along with a previously issued Canadian patent, are equivalents of US patent 5,952,644 and protect the concept of imaging and activating a photodynamic therapy agent in an optical CT scanner, a combined diagnostic and therapeutic system.

European patent EP01005286, issued July 2004, and Hong Kong patent HK1029508, issued December 2004, both entitled �Method for Reconstructing the Image of an Object Scanned with a Laser Imaging Apparatus,� are equivalents of US patent 6,130,958. These 2 patents protect the image reconstruction algorithms employed in CTLM technologies.
Hong Kong patent HK1029506, issued December 2004, entitled �Device for Determining the Contour of the Surface of an Object Being Scanned,� is equivalent to US patent 6,044,288. It, along with a previously issued European patent, protects the perimeter-measurement technique employed in the CTLM, which is essential to reconstructing optical CT images.
Chinese patent ZL01809326.4, entitled �Multiple Wavelength Simultaneous Data Acquisition Device for Breast Imaging,� issued in November 2005. This patent, equivalent to US patent 6,571,116, protects the concept of multiple wavelength optical data acquisition in an optical CT scanner for the purpose of tissue characterization.
European patent EP01389441, issued May 2006, entitled �Diagnostic Tomographic Laser Imaging Apparatus.� This patent, equivalent to US patent 5,692,511, protects the basic CTLM optical CT concept.
The CTLM system is a new continuous wave laser breast imaging system that utilizes state-of-the-art technology and patented algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to radiation or require breast compression. In the United States, Imaging Diagnostic Systems is seeking FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography (CTLM�) system to be used as an adjunct to mammography. The FDA has determined that the Company�s clinical investigation is a non-significant risk (NSR) investigational device study because it does not meet the definition of a significant risk (SR) device under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The Imaging Diagnostic Systems CTLM system has received other registrations including CE, CMDCAS Canadian Li
cense, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.
As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company�s filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.
Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com

############################
You are subscribed to the following list: IMDS Investor Relations
Using the following email:
example@example.com
You may automatically unsubscribe from this list at any time by
visiting the following URL: <http://www.imds.com/cgi-bin/dada/mail.cgi/u/investor-relations/>;
If the above URL is inoperable, make sure that you have copied the
entire address. You may also change your subscription by
visiting this list's main screen:
<http://www.imds.com/cgi-bin/dada/mail.cgi/list/investor-relations>;
Imaging Diagnostic Systems, Inc. - 6531 NW 18th Court - Plantation, Florida 33313
Tel: 954.581.9800 / Fax: 954.581.0555
<mailto:obrien@imds.com>

IMDS Investor Relations Message

Imaging Diagnostic Systems Announces CTLM Procedure Payment Approval In Beijing China
Hospitals Now Permitted To Charge For CT Laser Breast Imaging Exams
Fort Lauderdale, Florida, December 11, 2006 -Imaging Diagnostic Systems, Inc., (OTCBB:IMDS), a pioneer in laser optical breast imaging systems, announced that hospitals in the Beijing, China area may now charge patients for CT Laser Mammography (CTLM�) breast imaging procedures.
According to the Beijing Municipal Commission of Development & Reform and the Beijing Municipal Health Bureau, CTLM procedures may be priced up to RMB300 ($38 at the current exchange rate) per breast as listed on the �Interim Procedures for Beijing Medical Service Price� schedule. Imaging Diagnostic Systems had previously registered their CTLM system with the State Food and Drug Administration of the People�s Republic of China (SFDA); the equivalent of the US Food and Drug Administration.
�We have been anticipating this price schedule listing following our SFDA registration and the successful introduction of CT Laser Mammography at Beijing Friendship Hospital�, stated Tim Hansen, IDSI Chief Executive Officer. �Now that this first approval to charge patients has issued we expect other institutions to add our new laser imaging capabilities to their breast imaging services. We are also pursing similar listings at the National level and in other regions. All of this is very good news for our global commercialization program and for the Chinese women who will now gain access to our new non-invasive procedure for detecting and evaluating breast cancer cases�, he continued.
China sources report that the incidence of breast cancer in China has increased by at least 27% over the past decade and 40% of the Chinese women diagnosed with breast cancer die within five years because the cancer is already very advanced when it is diagnosed.
The CTLM system is a new continuous wave laser breast imaging system and utilizes state-of-the-art technology and patented algorithms to create 3-D images of the breast. The procedure is non-invasive, painless and does not expose the patient to radiation or require breast compression. In the United States, Imaging Diagnostic Systems is seeking FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography (CTLM�) system to be used as an adjunct to mammography. The FDA has determined that the Company�s clinical investigation is a non-significant risk (NSR) investigational device study because it does not meet the definition of a significant risk (SR) device under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The Imaging Diagnostic Systems CTLM system has received other registrations including CE, CMDCAS Canadian Lice
nse, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.
As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company�s filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.
Investor Relations:

############################
You are subscribed to the following list: IMDS Investor Relations
Using the following email:
example@example.com
You may automatically unsubscribe from this list at any time by
visiting the following URL: <http://www.imds.com/cgi-bin/dada/mail.cgi/u/investor-relations/>;
If the above URL is inoperable, make sure that you have copied the
entire address. You may also change your subscription by
visiting this list's main screen:
<http://www.imds.com/cgi-bin/dada/mail.cgi/list/investor-relations>;
Imaging Diagnostic Systems, Inc. - 6531 NW 18th Court - Plantation, Florida 33313
Tel: 954.581.9800 / Fax: 954.581.0555
<mailto:obrien@imds.com>

IMDS Investor Relations Message/CEOinterview to listen

http://www.wallst.net/audio/audio.asp?symbol=IMDS&id=2887

############################
You are subscribed to the following list: IMDS Investor Relations
Using the following email:
example@example.com
You may automatically unsubscribe from this list at any time by
visiting the following URL: <http://www.imds.com/cgi-bin/dada/mail.cgi/u/investor-relations/>;
If the above URL is inoperable, make sure that you have copied the
entire address. You may also change your subscription by
visiting this list's main screen:
<http://www.imds.com/cgi-bin/dada/mail.cgi/list/investor-relations>;
Imaging Diagnostic Systems, Inc. - 6531 NW 18th Court - Plantation, Florida 33313
Tel: 954.581.9800 / Fax: 954.581.0555
<mailto:obrien@imds.com>

IMDS Investor Relations Message

Dear Fellow Shareholder,
It is my pleasure to issue this shareholder letter in advance of our November 8th annual shareholder�s meeting. We want you to be well informed about progress on our key initiatives and to share our enthusiasm for the future.
Priority one, the CT Laser Mammography PMA, is moving forward with installations in a number of prestigious U.S. sites, although the process of securing sites in general has not progressed as quickly as we had anticipated. As I noted in an earlier letter, the FDA determined that CTLM� trials under our intended use would constitute a Non-Significant Risk device study; we assumed such a reclassification would have enabled us to more quickly engage U.S. clinical �partners.� We found, however, that the processes through Investigational Review Boards and legal departments had become much more complex and lengthy in recent years. We also experienced delays because many of our preferred sites were simply too busy to participate in our study due to serious understaffing and workload issues, a recurring theme in the larger departments we contacted. Consequently, we needed to approach many more prospective sites than originally intended. As we work towards finalizing the remaining
sites, we are continuing to contact others as back-ups. Our practice is to limit public identification of the sites so that the study members may participate without publicity or distraction.
We previously stated our plans to update all CTLMs shipped to PMA sites with the latest hardware and software developments to best reflect the system�s capabilities as an adjunctive breast imaging tool. Sites are using the latest CTLM configurations. Because the CTLM imaging technique is completely new to doctors and technologists and training could affect results, we improved our certified training programs and added computerized calibration and QA software to the systems. These improvements take full advantage of the experience we have gained through our 7,500 international breast exams and our service histories.
There remain uncertainties about the time it may take to accrue the total number of cases needed for final PMA submission because each site has a unique workload and patient volunteer recruitment process. Internally, we have an excellent team of staff radiologists, applications specialists, data managers, and service engineers on the PMA project. That excellence extends to the prestigious institutions and mammographers we have chosen; the outside PMA services of King & Spalding, a leading regulatory law firm; the
independent biometric firm performing our statistical analyses; the study auditing and monitoring firm, M Squared Associates; and other associates. I believe the PMA process is well in hand and fully resourced.
Our Global Commercialization initiatives have been given additional resources to speed up the pace of target market penetration. We have dedicated additional marketing resources to Mexico, Central and South America, and we installed demonstration sites in Argentina and in a private clinic in Colombia. Recently, we added an exclusive distributor in Mexico and received regulatory approval to sell CTLM systems in Brazil, where we are in the final stage of distributor selection.
In the Asia-Pacific Region, we contracted with BAC, Inc. to manage our existing distributors and develop new areas. BAC is now managing our China distributor activities and has led IDSI in establishing a representative office in Beijing. We have a full-time manager (BAC contract), a marketing specialist, and we plan to add a lead service supervisor: three dedicated Chinese nationals in Beijing. Clinical studies at our Beijing hospital site are going well, and, although we have the Chinese clinical studies needed, the process to gain CTLM procedure reimbursement status has been particularly long. We expect reimbursement to be announced very soon, which will greatly enhance the attractiveness of CTLM to the market.
Elsewhere in the Asia-Pacific region, BAC is pursuing business connections in Australia, Singapore, Malaysia, New Zealand, Hong Kong, Macao, Taiwan, and the Philippines to enhance our existing representation in South Korea and China. We have signed an exclusive distributor in Malaysia, where interest in breast cancer detection and treatment is surging due to publicity surrounding their First Lady, who succumbed to the disease. We are pleased with BAC�s efforts, and we are gaining momentum through their experience and connections.
Activities in Europe and the Middle East are top priorities for our International Sales VP, who highlighted progress by holding the first IDSI Users Meeting last April in Berlin. Our international users have been doing excellent clinical work and have contributed to our Image Interpretation Manual and User Training Program. Earlier this year, we received an order for six CTLM systems from our Polish distributor. The first of those systems shipped in June, giving us three systems in Poland, all serving major oncology centers. The remaining CTLM units on the order have not yet been scheduled for shipment. Among our global users, we have three systems operating in Poland, four in Italy, two each in the Czech Republic and the United Arab Emirates, as well as systems in Germany and Austria; all are adding to CTLM�s growing clinical presence in the regions. In September, we added an exclusive distributor responsible for Norway, Sweden and Denmark.
Our expanded approach involving the three regions described above has increased our Global Commercialization investment, which we believe will increase short-term sales and accelerate market acceptance.
We remain tightly focused on women�s health opportunities as we continue to explore optical molecular imaging and image fusion research projects involving fluorescent markers and methods to highlight and quantify the angiogenesis process. As a pioneer in laser breast imaging, it is gratifying to see others now recognize the technological and clinical potential. Late in 2005, we noted that Philips Medical Systems had entered the laser optical scanning arena with a joint Schering AG program. Notably, Philips stated in a recent publication that they will use continuous wave near-infrared (NIR) methodologies; this supports our technological approach over the ART alternatives. GE Medical is also stepping up activity and has installed several ART optical imaging systems in North America to collect PMA data. We also believe Siemens Medical has optical breast imaging devices under development. In the past 18 months, there has been a substantial increase in the number of MRI bre
ast examinations and publications which validate the relationship of angiogenesis to breast cancer and the fundamental capability of imaging the angiogenesis process. We see these developments as very positive, as they validate our position that imaging angiogenesis in the breast is both clinically useful and commercially attractive. IDSI�s leadership is well demonstrated in the large number of clinical exams we have completed, in our patent position, and in the fact that only CTLM uses true CT continuous wave laser breast imaging techniques.
In August, we concluded a major licensing transaction concerning our Laser Imaging for Lab Animals (LILA) technology. As I noted in my first shareholders letter, LILA has great optical molecular imaging potential, but is not, strictly speaking, a women�s health technology. We, therefore, chose to license our animal imaging technologies to Bioscan, Inc., a company operating in that market and who possesses the capability to commercialize LILA technologies. IDSI will receive a front-end license fee and substantial royalties on future Bioscan sales. As a result, we will receive the economic benefits of this project much sooner with Bioscan than if we had pursued it on our own. Furthermore, licensing LILA permits IDSI to focus on our core business in women�s health markets and on the development of a family of laser breast imaging systems. We believe the license agreement enhances IDSI shareholder value economically and strategically.
Fellow shareholders, we have a great team behind these initiatives. Every IDSI associate is motivated to fulfill our mission and to improve breast cancer detection and case management methods. Our technology is unique and revolutionary, and has the potential to become a family of related systems. It serves us well to remember that other new imaging technologies such as CT and MRI started small, but over time, grew to become mainstream tools. We see that opportunity in laser breast imaging.
On behalf of all IDSI employees and our customers, we thank you for your support and patience. We look forward to seeing you at our annual meeting on November 8th in Florida.

Sincerely,

Tim Hansen

############################
You are subscribed to the following list: IMDS Investor Relations
Using the following email:
example@example.com
You may automatically unsubscribe from this list at any time by
visiting the following URL: <http://www.imds.com/cgi-bin/dada/mail.cgi/u/investor-relations/>;
If the above URL is inoperable, make sure that you have copied the
entire address. You may also change your subscription by
visiting this list's main screen:
<http://www.imds.com/cgi-bin/dada/mail.cgi/list/investor-relations>;
Imaging Diagnostic Systems, Inc. - 6531 NW 18th Court - Plantation, Florida 33313
Tel: 954.581.9800 / Fax: 954.581.0555
<mailto:obrien@imds.com>

IMDS Investor Relations Message previous press release

Monday, May 1, 2006 :: Imaging Diagnostic Systems� CT Laser Breast Imaging Scanner
Imaging Diagnostic Systems� CT Laser Breast Imaging Scanner
Enters US FDA Clinical Trials
Fort Lauderdale, Florida, May 1, 2006�Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) announced today that clinical trials of the CT Laser Mammography (CTLM�) system have commenced at a number of US university medical centers. IDSI will collect clinical data through a non-significant risk (NSR) device study.
�As previously reported, we will be scanning patients using the latest version of the CTLM system,� commented Deborah O�Brien, Senior Vice President of Imaging Diagnostic Systems. �Following data collection and analysis, we intend to submit a Premarket Approval application to the FDA for the use of CTLM as an imaging adjunct to conventional diagnostic mammography. CTLM has the potential to fill an important role in improving the accuracy of current breast cancer detection methods and in improving patient management. We are partnering with prestigious institutions, using an experienced clinical study management firm, working with leading regulatory consultants, and using our best efforts to ensure successful clinical trials.�
�We are also moving forward in our global commercialization efforts. We held our first International CTLM Users Meeting in April. Many of our international users have gained useful experience and collectively have scanned over 7,000 breasts. IDSI recently participated in the European Congress of Radiology, where several of our luminary partners presented clinical studies,� O�Brien added.
The Company will continue to provide periodic updates of its progress on current initiatives, including the US PMA process, by way of shareholder letters, press releases, and other public filings. The locations of the clinical trials will not be disclosed so that the study members may participate without publicity or distraction.
Imaging Diagnostic Systems is seeking FDA Premarket Approval (PMA) for its Computed Tomography Laser Mammography (CTLM�) system to be used as an adjunct to mammography. The Company's PMA application will be submitted in its entirety at the completion of the data collection and review process. The FDA has determined that the Company�s clinical investigation is a non-significant risk (NSR) investigational device study because it does not meet the definition of a significant risk (SR) device under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL li
sting, ISO 9001:2000, ISO 13485:2003 certification and FDA export certification for its CT Laser Mammography system.
Please visit Imaging Diagnostic Systems� website at: www.imds.com for additional information.
In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company�s filing with the Securities Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.
Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com

############################
You are subscribed to the following list: IMDS Investor Relations
Using the following email:
example@example.com
You may automatically unsubscribe from this list at any time by
visiting the following URL: <http://www.imds.com/cgi-bin/dada/mail.cgi/u/investor-relations/>;
If the above URL is inoperable, make sure that you have copied the
entire address. You may also change your subscription by
visiting this list's main screen:
<http://www.imds.com/cgi-bin/dada/mail.cgi/list/investor-relations>;
Imaging Diagnostic Systems, Inc. - 6531 NW 18th Court - Plantation, Florida 33313
Tel: 954.581.9800 / Fax: 954.581.0555
<mailto:obrien@imds.com>

IMDS Investor Relations Message

maging Diagnostic Systems Adds Malaysia, Mexico, Sweden, Denmark and Norway Distributors
Fort Lauderdale, Florida, September 26, 2006�Imaging Diagnostic Systems, Inc., (OTCBB:IMDS), a pioneer in laser optical breast imaging, has signed three exclusive distributors and added five countries to its global distribution network. These additions will increase market awareness of the new CT Laser Mammography (CTLM�) technology for women in the regions.
Able Global, an experienced multimodality imaging distributor, will address the growing need in Malaysia for improved breast cancer detection as IDSI�s exclusive distributor. According to the Malaysian National Cancer Registry, breast cancer is the most common cancer in Malaysian women and the number of breast cancer cases is on the rise. Since the October 2005 passing of Malaysia�s First Lady from breast cancer, there has been an increased emphasis on breast cancer detection and treatment throughout Malaysia.
IDSI�s Latin and South American distributor network will expand into Mexico as Mayerick, S.A. de C.V., one of the first radiological distributors in Mexico, begins exclusive CTLM distribution in Mexico. According to the Mexican Histopathological Registry of Neoplasias, breast cancer is the second most common type of cancer in women and the rates of new cases and deaths are increasing.
HAWA Imaging AB, an experienced medical imaging equipment distributor in Sweden, will become part of IDSI�s European Region and have exclusive coverage in Sweden, Denmark, and Norway. According to the European Network of Cancer Registries, Northern European countries, particularly Denmark and Sweden, have some of the highest incidence rates of breast cancer in Europe.
�We are pleased to announce additions to three of our global regions. Asia-Pacific, Latin and South America, and greater Europe each hold tremendous opportunities for commercialization of CTLM. Our latest distributors are experienced in the diagnostic imaging capital equipment business and have excellent customer relationships,� stated Tim Hansen, IDSI Chief Executive Officer. �Malaysia and Mexico add substantially to our global geographic coverage. Historically, there have been many scientific and clinical breast imaging developments from Scandinavia, so we anticipate an excellent reception to our new laser breast imaging technology there.�
Imaging Diagnostic Systems is seeking FDA Premarket Approval (PMA) for its Computed Tomography Laser Mammography (CTLM�) system to be used as an adjunct to mammography. The FDA has determined that the Company�s clinical investigation is a non-significant risk (NSR) investigational device study because it does not meet the definition of a significant risk (SR) device under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. The CTLM system is limited by United States Federal Law to investigational use only in the United States. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:
2000, ISO 13485:2003 certification and FDA export certification for its CT Laser Mammography system.
As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company�s filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.
Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com

############################
You are subscribed to the following list: IMDS Investor Relations
Using the following email:
example@example.com
You may automatically unsubscribe from this list at any time by
visiting the following URL: <http://www.imds.com/cgi-bin/dada/mail.cgi/u/investor-relations/>;
If the above URL is inoperable, make sure that you have copied the
entire address. You may also change your subscription by
visiting this list's main screen:
<http://www.imds.com/cgi-bin/dada/mail.cgi/list/investor-relations>;
Imaging Diagnostic Systems, Inc. - 6531 NW 18th Court - Plantation, Florida 33313
Tel: 954.581.9800 / Fax: 954.581.0555
<mailto:obrien@imds.com>

IMDS Investor Relations Message

Imaging Diagnostic Systems� CT Laser Breast Imaging Scanner
Enters US FDA Clinical Trials
Fort Lauderdale, Florida, May 1, 2006�Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) announced today that clinical trials of the CT Laser Mammography (CTLM�) system have commenced at a number of US university medical centers. IDSI will collect clinical data through a non-significant risk (NSR) device study.
�As previously reported, we will be scanning patients using the latest version of the CTLM system,� commented Deborah O�Brien, Senior Vice President of Imaging Diagnostic Systems. �Following data collection and analysis, we intend to submit a Premarket Approval application to the FDA for the use of CTLM as an imaging adjunct to conventional diagnostic mammography. CTLM has the potential to fill an important role in improving the accuracy of current breast cancer detection methods and in improving patient management. We are partnering with prestigious institutions, using an experienced clinical study management firm, working with leading regulatory consultants, and using our best efforts to ensure successful clinical trials.�
�We are also moving forward in our global commercialization efforts. We held our first International CTLM Users Meeting in April. Many of our international users have gained useful experience and collectively have scanned over 7,000 breasts. IDSI recently participated in the European Congress of Radiology, where several of our luminary partners presented clinical studies,� O�Brien added.
The Company will continue to provide periodic updates of its progress on current initiatives, including the US PMA process, by way of shareholder letters, press releases, and other public filings. The locations of the clinical trials will not be disclosed so that the study members may participate without publicity or distraction.

Imaging Diagnostic Systems is seeking FDA Premarket Approval (PMA) for its Computed Tomography Laser Mammography (CTLM�) system to be used as an adjunct to mammography. The Company's PMA application will be submitted in its entirety at the completion of the data collection and review process. The FDA has determined that the Company�s clinical investigation is a non-significant risk (NSR) investigational device study because it does not meet the definition of a significant risk (SR) device under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval,
UL listing, ISO 9001:2000, ISO 13485:2003 certification and FDA export certification for its CT Laser Mammography system.
Please visit Imaging Diagnostic Systems� website at: www.imds.com for additional information.
In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company�s filing with the Securities Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.
Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com

############################
You are subscribed to the following list: IMDS Investor Relations
Using the following email:
example@example.com
You may automatically unsubscribe from this list at any time by
visiting the following URL: <http://www.imds.com/cgi-bin/dada/mail.cgi/u/investor-relations/>;
If the above URL is inoperable, make sure that you have copied the
entire address. You may also change your subscription by
visiting this list's main screen:
<http://www.imds.com/cgi-bin/dada/mail.cgi/list/investor-relations>;
Imaging Diagnostic Systems, Inc. - 6531 NW 18th Court - Plantation, Florida 33313
Tel: 954.581.9800 / Fax: 954.581.0555
<mailto:obrien@imds.com>

IMDS Investor Relations Message

IMAGING DIAGNOSTIC SYSTEMS FEATURES
CT LASER MAMMOGRAPHY CLINICAL STUDIES IN BRAZIL
Clinical Cases to be Exhibited at 36th Annual S�o Paulo Society of Radiology Meeting
Fort Lauderdale, Florida, April 19, 2006�Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) will display CT Laser Mammography (CTLM�) clinical cases from international Luminary Partner sites at the 36th annual meeting of the S�o Paulo Society of Radiology, April 20 - 23 in S�o Paulo, Brazil. The cases highlight the capability of CTLM to image angiogenesis, usually associated with breast cancer.
IDSI has announced plans to commercialize the CTLM system throughout Central and South America; this exhibition marks the third major South American conference attended in less than ten months.
The annual meeting of the S�o Paulo Society of Radiology, Jornada Paulista de Radiologia (JPR) is one of the most important radiological meetings, featuring physician review courses, technical exhibits, symposia, and commercial exhibits. The meeting attracts prominent Brazilian and international radiologists.
IDSI will be located at booth #35 with Pyramid Medical Systems, one of Brazil�s largest medical device distributors.
Imaging Diagnostic Systems is seeking FDA Premarket Approval (PMA) for its Computed Tomography Mammography (CTLM�) system to be used as an adjunct to mammography. The Company's PMA application will be submitted in its entirety at the completion of the data collection and review process. The FDA has determined that the Company�s clinical investigation is a non-significant risk (NSR) investigational device study because it does not meet the definition of a significant risk (SR) device under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA ap
proval, UL listing, ISO 9001:2000-13485 certification and FDA export certification for its CT Laser Mammography system.
Please visit Imaging Diagnostic Systems� website at: www.imds.com for additional information.
In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company�s filing with the Securities Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

############################
You are subscribed to the following list: IMDS Investor Relations
Using the following email:
example@example.com
You may automatically unsubscribe from this list at any time by
visiting the following URL: <http://www.imds.com/cgi-bin/dada/mail.cgi/u/investor-relations/>;
If the above URL is inoperable, make sure that you have copied the
entire address. You may also change your subscription by
visiting this list's main screen:
<http://www.imds.com/cgi-bin/dada/mail.cgi/list/investor-relations>;
Imaging Diagnostic Systems, Inc. - 6531 NW 18th Court - Plantation, Florida 33313
Tel: 954.581.9800 / Fax: 954.581.0555
<mailto:obrien@imds.com>

IDSI Signs 8th CT Laser Mammography Site To Complete Luminary And Research Network

Fort Lauderdale, Florida, May 9, 2005�Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) announced installation of the 8th luminary and research CT Laser Mammography system. The latest CTLM� was placed at the prestigious Gazi University Hospital, Ankara, Turkey where researchers have already begun breast scanning procedures.

A. �zdemir, M.D., Associate Professor, Department of Radiology, said, �We are anxious to show that the CT Laser Mammography technology substantially complements the conventionally used x-ray mammography, especially in the area of functional imaging. We have a lot of experience and expertise in early breast cancer detection especially in addressing the difficulties of imaging dense breasts where ultrasound may have been the preferred imaging technique. Our findings with CTLM may be of utmost importance for imaging centers seeking to stay current with the latest imaging developments.�

According to the Company the eight systems in this luminary network include:

Gazi University Hospital, Ankara, Turkey
Charles University Hospital, Prague, Czech Republic
Catholic University Hospital, Rome, Italy
Comprehensive Cancer Centre, Gliwice, Poland
Robert-R�ssle Clinic, Buch, Germany
University of Muenster Hospital, Munster, Germany
Charite Hospital, Berlin, Germany
Vienna General Hospital, Vienna, Austria

Deborah O�Brien, Senior Vice President, said, �IDSI has been commercializing the CTLM in many global markets and we previously announced our plans to set up this network to foster research and to promote the technology in local markets. We will continue to support similar programs in China and in other global regions. These investments may accelerate CTLM market acceptance while providing valuable clinical experiences. With respect to Gazi, we are particularly pleased to have Professor �zdemir in our network to focus on using CTLM as an adjunct to current procedures.�

The CTLM system is the first patented breast imaging system that utilizes state-of the-art laser technology and patented algorithms to create 3-D cross- sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLM system to be used as an adjunct to mammography.

Please visit Imaging Diagnostic Systems� website at: www.imds.com for additional information.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company�s filing with the Securities Exchange Commission.

IMDS Investor Relations Message

Tim Hansen, CEO of Imaging Diagnostic Systems, was interviewed for the latest issue of The Wall Street Trancript (TWST). TWST has a subscription base of approximately 6,000 money managers, analysts, investment brokers, mutual funds etc. (30,000 individual readers).

LC Group
404-261-1196

--------------------------------------------------------
Company Interview Excerpt
TIM HANSEN - IMAGING DIAGNOSTIC SYSTEMS INC (IMDS)
Full article published: 4/18/2005

TWST: We'd like to begin with a brief historical sketch of Imaging Diagnostic Systems and a picture of things as they are now. Mr. Hansen: The company has been in existence for almost a decade and it started with the same concept it's pursuing today. That is to find a way to detect breast cancer without the use of ionizing radiation and more specifically, with the use of passive laser light. Our device was intended to deal a blow to what was then and certainly is now a major medical problem: many women receive traumatic biopsies, thinking they have breast cancer, but the biopsies later prove to be negative and unnecessary. When the company started, it had to deal with some severe technical issues that had prevented lasers from being used in medical imaging. The problem was that once light is projected through tissue, it refracts, scatters and does a number of odd things, and so it's very difficult to simplistically shine a laser or any light through a breast and receive a usa ble signal on the other side. However, the inventor, Richard Grable, figured this out and also figured out how to use a computer to create an image in much the way a CT does. By taking sequential slices of the breast, using the laser as the energy source and with a detector opposing it, and a back projector and a fancy computer algorithm, he turned that laser signal into a medical image.

When Richard started the company, the other technical issue was that lasers in those days were about the size of an executive office desk. They weren't actually that packagable and were certainly very expensive.

Today, lasers are small enough to be put into a pointer. Those technical developments through the years gave us the opportunity to create what we consider a very usable technology that we assume is going to evolve into a family of breast imaging products. That was then, and here we are today with a product that's approved in many countries outside the United States and which has already scanned better than 4,500 individual breasts.